Company: PCRX
Filing Date: 2025-04-18
Form Type: DEFA14A
Source: 0001396814-25-000053
Chunk: 0

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-18
Form: DEFA14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of

#### the Securities Exchange Act of 1934
Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

| ¨ |     | Preliminary Proxy Statement                                                     |
| ¨ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ |     | Definitive Proxy Statement                                                      |
| ¨ |     | Definitive Additional Materials                                                 |
| x |     | Soliciting Material under §240.14a-12                                           |

#### PACIRA BIOSCIENCES, INC.
<div align='center'>(Name of Registrant as Specified in Its Charter)</div>

<div align='center'>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x |     | No fee required.                                                                                    |
| ¨ |     | Fee paid previously with preliminary materials.                                                     |
| ¨ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

On April 17, 2025, Pacira BioSciences, Inc. sent the following note to employees:

Subject: Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Dear Colleagues,

Today, we announced our commitment to increasing shareholder value through a series of additional strategic steps aimed at improving performance and driving long-term growth.

Since launching our 5x30 strategy to become a leading biopharmaceutical company in musculoskeletal pain and adjacencies, we've made steady progress toward that vision.

Building on that momentum, we're introducing new initiatives aimed at delivering even greater value, including:

•

#### Repurchase Authorization
. The Board of Directors has authorized a share repurchase program of up to an aggregate of $300 million with respect to the company’s common stock, under the same terms as the authorization announced on May 7, 2024 and replacing the prior authorization. The Pacira Board and management team remain committed to a diligent, strategic approach to repurchases that aligns with the company’s long-term objectives and enhances shareholder